Your browser doesn't support javascript.
Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses.
Buscot, Matthieu; Cremoni, Marion; Graça, Daisy; Brglez, Vesna; Courjon, Johan; Allouche, Jonathan; Teisseyre, Maxime; Boyer, Laurent; Barrière, Jérôme; Chamorey, Emmanuel; Carles, Michel; Seitz-Polski, Barbara.
  • Buscot M; Infectious Diseases Department, Nice University Hospital, Nice, France.
  • Cremoni M; Immunology Laboratory, Archet 1 Hospital, Nice University Hospital, Nice, France.
  • Graça D; Clinical Research Unit Côte d'Azur (UR2CA), Côte d'Azur University, Nice, France.
  • Brglez V; Immunology Laboratory, Archet 1 Hospital, Nice University Hospital, Nice, France.
  • Courjon J; Immunology Laboratory, Archet 1 Hospital, Nice University Hospital, Nice, France.
  • Allouche J; Clinical Research Unit Côte d'Azur (UR2CA), Côte d'Azur University, Nice, France.
  • Teisseyre M; Infectious Diseases Department, Nice University Hospital, Nice, France.
  • Boyer L; Mediterranean Center for Molecular Medicine (C3M), Côte d'Azur University, Nice, France.
  • Barrière J; Clinical Research Unit Côte d'Azur (UR2CA), Côte d'Azur University, Nice, France.
  • Chamorey E; Clinical Research Unit Côte d'Azur (UR2CA), Côte d'Azur University, Nice, France.
  • Carles M; Mediterranean Center for Molecular Medicine (C3M), Côte d'Azur University, Nice, France.
  • Seitz-Polski B; Department of Oncology, Clinique St Jean, Cagnes sur Mer, France.
Front Immunol ; 14: 1145652, 2023.
Article in English | MEDLINE | ID: covidwho-2292746
ABSTRACT

Introduction:

COVID-19 vaccines are expected to provide effective protection. However, emerging strains can cause breakthrough infection in vaccinated individuals. The immune response of vaccinated individuals who have experienced breakthrough infection is still poorly understood.

Methods:

Here, we studied the humoral and cellular immune responses of fully vaccinated individuals who subsequently experienced breakthrough infection due to the Delta variant of SARS-CoV-2 and correlated them with the severity of the disease.

Results:

In this study, an effective humoral response alone was not sufficient to induce effective immune protection against severe breakthrough infection, which also required effective cell-mediated immunity to SARS-CoV-2. Patients who did not require oxygen had significantly higher specific (p=0.021) and nonspecific (p=0.004) cellular responses to SARS-CoV-2 at the onset of infection than those who progressed to a severe form.

Discussion:

Knowing both humoral and cellular immune response could allow to adapt preventive strategy, by better selecting patients who would benefit from additional vaccine boosters. Trial registration numbers https//clinicaltrials.gov, identifier NCT04355351; https//clinicaltrials.gov, identifier NCT04429594.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2023 Document Type: Article Affiliation country: Fimmu.2023.1145652

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Front Immunol Year: 2023 Document Type: Article Affiliation country: Fimmu.2023.1145652